- Welcome to Ryan's District Boards.
Posted by 0225ml46
- January 24, 2011, 08:42:20 AMIn an earlier pilot study with nine smokers, Killen and colleagues found that the selegiline patch helped smokers quit,You are not allowed to view links.
Register or Login, at least in the short term, but more interesting were their experiences during the process. Many of the participants said they felt calm and relaxed--a stark contrast to the usual anxiety and edginess experienced by people who try to stop, Killen said.
Interested participants should contact study coordinator Dalea Fong at (866) 218-7848 or You are not allowed to view links. Register or Login. Participants need to currently smoke at least 10 cigarettes a day.
The medication, which is marketed under the name Emsam, is produced by Somerset Pharmaceuticals and Bristol-Meyers Squibb. The Food and Drug Administration approved the patch as an antidepressant treatment in February 2006.
For two months, the participants will go to a Stanford smoking cessation clinic in San Jose for weekly checkups. During these visits, participants will also receive individual counseling to help them stay smoke-free. The study will follow participants for a full year to track their progress at quitting.
Medication delivery by patch offers a potential advantage over a pill by reducing side effects and providing a higher,You are not allowed to view links. Register or Login, more consistent level of the medication, Killen said.
Besides easing urges, the medication offers other benefits to smokers trying to quit, Killen said. "Many smokers develop symptoms of depression" after they quit, he said. Because selegiline is an antidepressant, it could stave off those feelings.
The National Institute on Drug Abuse is funding the study, which will last for four years.
If the medication can help alleviate those symptoms, smokers will not only have an easier time quitting,You are not allowed to view links. Register or Login, but may be less likely to start smoking again,You are not allowed to view links. Register or Login, Killen said.
The study seeks smokers between the ages of 18 and 65 who are interested in quitting, said Killen. Participants will wear a patch on their skin that delivers either selegiline or a placebo. Participants put on a new patch each day for eight weeks while trying to quit smoking.
Researchers at the Stanford Prevention Research Center are looking for regular smokers to try a skin patch that delivers a medication used to treat depression. The drug, selegiline, could help smokers combat the cravings they feel when they try to quit, said study leader Joel Killen, PhD, professor of medicine.
Doctors already prescribe antidepressants, such as bupropion (marketed as Zyban and Wellbutrin), to help smokers quit, but Killen's study is the first to use an antidepressant patch to help smokers kick the habit.
"The issue is whether and to what extent you can produce long-term abstinence," he said.
Study Will Test Antidepressant Patch That May Help Smokers Kick The Habit
Interested participants should contact study coordinator Dalea Fong at (866) 218-7848 or You are not allowed to view links. Register or Login. Participants need to currently smoke at least 10 cigarettes a day.
The medication, which is marketed under the name Emsam, is produced by Somerset Pharmaceuticals and Bristol-Meyers Squibb. The Food and Drug Administration approved the patch as an antidepressant treatment in February 2006.
For two months, the participants will go to a Stanford smoking cessation clinic in San Jose for weekly checkups. During these visits, participants will also receive individual counseling to help them stay smoke-free. The study will follow participants for a full year to track their progress at quitting.
Medication delivery by patch offers a potential advantage over a pill by reducing side effects and providing a higher,You are not allowed to view links. Register or Login, more consistent level of the medication, Killen said.
Besides easing urges, the medication offers other benefits to smokers trying to quit, Killen said. "Many smokers develop symptoms of depression" after they quit, he said. Because selegiline is an antidepressant, it could stave off those feelings.
The National Institute on Drug Abuse is funding the study, which will last for four years.
If the medication can help alleviate those symptoms, smokers will not only have an easier time quitting,You are not allowed to view links. Register or Login, but may be less likely to start smoking again,You are not allowed to view links. Register or Login, Killen said.
The study seeks smokers between the ages of 18 and 65 who are interested in quitting, said Killen. Participants will wear a patch on their skin that delivers either selegiline or a placebo. Participants put on a new patch each day for eight weeks while trying to quit smoking.
Researchers at the Stanford Prevention Research Center are looking for regular smokers to try a skin patch that delivers a medication used to treat depression. The drug, selegiline, could help smokers combat the cravings they feel when they try to quit, said study leader Joel Killen, PhD, professor of medicine.
Doctors already prescribe antidepressants, such as bupropion (marketed as Zyban and Wellbutrin), to help smokers quit, but Killen's study is the first to use an antidepressant patch to help smokers kick the habit.
"The issue is whether and to what extent you can produce long-term abstinence," he said.
Study Will Test Antidepressant Patch That May Help Smokers Kick The Habit